Prostate cancer proteomics: clinically useful protein biomarkers and future perspectives

References

• American Cancer Society. Cancer facts & figures 2016. Atlanta (GA): American Cancer Society; 2016.
   Google Scholar
• Tosoian J. Loeb S. PSA and beyond: the past, present, and future of investigative biomarkers for prostate cancer. Sci World J. 2010;10:1919–1931.
   Google Scholar
• Kim Y, Kislinger T. Novel approaches for the identification of biomarkers of aggressive prostate cancer. Genome Med. 2013;5:56.
   PubMed Web of Science ®Google Scholar
• Davalieva K, Polenakovic M. Proteomics in diagnosis of prostate cancer. Pril Makedon Akad Na Nauk Umet Oddelenie Za Med Nauki. 2015;36:5–36.
   PubMedGoogle Scholar
• Drake RR, Kislinger T. The proteomics of prostate cancer exosomes. Expert Rev Proteomics. 2014;11:167–177.
   PubMedGoogle Scholar
• Davalieva K, Kostovska IM, Kiprijanovska S, et al. Proteomics analysis of malignant and benign prostate tissue by 2D DIGE/MS reveals new insights into proteins involved in prostate cancer. The Prostate. 2015;75:1586–1600.
   PubMed Web of Science ®Google Scholar
• Iglesias-Gato D, Wikström P, Tyanova S, et al. The proteome of primary prostate cancer. Eur Urol. 2016;69:942–952.
   PubMed Web of Science ®Google Scholar
• Del Giudice PT, da Silva BF, Lo Turco EG, et al. Changes in the seminal plasma proteome of adolescents before and after varicocelectomy. Fertil Steril. 2013;100:667–672.
   PubMed Web of Science ®Google Scholar
• Belardin LB, Del Giudice PT, Camargo M, et al. Alterations in the proliferative/apoptotic equilibrium in semen of adolescents with varicocele. J Assist Reprod Genet. 2016;33:1657–1664.
   PubMed Web of Science ®Google Scholar
• Del Giudice PT, Belardin LB, Camargo M, et al. Determination of testicular function in adolescents with varicocoele - a proteomics approach. Andrology. 2016;4:447–455.
   PubMed Web of Science ®Google Scholar
• Camargo M, Intasqui Lopes P, Del Giudice PT, et al. Unbiased label-free quantitative proteomic profiling and enriched proteomic pathways in seminal plasma of adult men before and after varicocelectomy. Hum Reprod Oxf Engl. 2013;28:33–46.
   PubMed Web of Science ®Google Scholar
• Zylbersztejn DS, Andreoni C, Del Giudice PT, et al. Proteomic analysis of seminal plasma in adolescents with and without varicocele. Fertil Steril. 2013;99:92–98.
   PubMed Web of Science ®Google Scholar
• Jiang F, He H, Zhang Y, et al. An integrative proteomics and interaction network-based classifier for prostate cancer diagnosis. PloS One. 2013;8:e63941.
   PubMed Web of Science ®Google Scholar
• Aiello D, Casadonte F, Terracciano R, et al. Targeted proteomic approach in prostatic tissue: a panel of potential biomarkers for cancer detection. Oncoscience. 2016;3:220–241.
   PubMedGoogle Scholar
• Webber JP, Spary LK, Mason MD, et al. Prostate stromal cell proteomics analysis discriminates normal from tumour reactive stromal phenotypes. Oncotarget. 2016;7:20124–20139.
   PubMed Web of Science ®Google Scholar
• Staunton L, Tonry C, Lis R, et al. Pathology-driven comprehensive proteomic profiling of the prostate cancer tumor microenvironment. Mol Cancer Res MCR. 2017;15:281–293.
   PubMed Web of Science ®Google Scholar
• Chen C, Shen H, Zhang L-G, et al. Construction and analysis of protein-protein interaction networks based on proteomics data of prostate cancer. Int J Mol Med. 2016;37:1576–1586.
   PubMed Web of Science ®Google Scholar
• SLC2A4 - Solute carrier family 2, facilitated glucose transporter member 4 - Homo sapiens (Human) - SLC2A4 gene & protein [Internet]. [cited 2017 Nov 21]. Available from: http://www.uniprot.org/uniprot/P14672
   Google Scholar
• TUBB4B - Tubulin beta-4B chain - Homo sapiens (Human) - TUBB4B gene & protein [Internet]. [cited 2017 Nov 21]. Available from: http://www.uniprot.org/uniprot/P68371
   Google Scholar
• Chen C, Zhang L-G, Liu J, et al. Bioinformatics analysis of differentially expressed proteins in prostate cancer based on proteomics data. OncoTargets Ther. 2016;9:1545–1557.
   PubMed Web of Science ®Google Scholar
• Chen J, Xi J, Tian Y, et al. Identification, prioritization, and evaluation of glycoproteins for aggressive prostate cancer using quantitative glycoproteomics and antibody-based assays on tissue specimens. Proteomics. 2013;13:2268–2277.
   PubMed Web of Science ®Google Scholar
• Liu Y, Chen J, Sethi A, et al. Glycoproteomic analysis of prostate cancer tissues by SWATH mass spectrometry discovers N-acylethanolamine acid amidase and protein tyrosine kinase 7 as signatures for tumor aggressiveness. Mol Cell Proteomics MCP. 2014;13:1753–1768.
   PubMed Web of Science ®Google Scholar
• Dunne JC, Lamb DS, Delahunt B, et al. Proteins from formalin-fixed paraffin-embedded prostate cancer sections that predict the risk of metastatic disease. Clin Proteomics. 2015;12:24.
   PubMed Web of Science ®Google Scholar
• Blume-Jensen P, Berman DM, Rimm DL, et al. Development and clinical validation of an in situ biopsy-based multimarker assay for risk stratification in prostate cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2015;21:2591–2600.
   PubMed Web of Science ®Google Scholar
• Shipitsin M, Small C, Choudhury S, et al. Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error. Br J Cancer. 2014;111:1201–1212.
   PubMed Web of Science ®Google Scholar
• Ferreira D, Adega F, Chaves R The importance of cancer cell lines as in vitro models in cancer methylome analysis and anticancer drugs testing. 2013 [cited 2017 Sep 25]. Available from: http://www.intechopen.com/books/oncogenomics-and-cancer-proteomics-novel-approaches-in-biomarkers-discovery-and-therapeutic-targets-in-cancer/the-importance-of-cancer-cell-lines-as-in-vitro-models-in-cancer-methylome-analysis-and-anticancer-d
   Google Scholar
• Burch TC, Watson MT, Nyalwidhe JO. Variable metastatic potentials correlate with differential plectin and vimentin expression in syngeneic androgen independent prostate cancer cells. PloS One. 2013;8:e65005.
   PubMed Web of Science ®Google Scholar
• Li Q, Li Y, Wang Y, et al. Quantitative proteomic study of human prostate cancer cells with different metastatic potentials. Int J Oncol. 2016;48:1437–1446.
   PubMed Web of Science ®Google Scholar
• Ai J, Lu Y, Wei Q, et al. Comparative proteomics uncovers correlated signaling network and potential biomarkers for progression of prostate cancer. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol. 2017;41:1–9.
   PubMed Web of Science ®Google Scholar
• Ai J, Jin T, Yang L, et al. Vinculin and filamin-C are two potential prognostic biomarkers and therapeutic targets for prostate cancer cell migration. Oncotarget. 2017;8(47):82430-82436.
   Web of Science ®Google Scholar
• Stewart PA, Khamis ZI, Zhau HE, et al. Upregulation of minichromosome maintenance complex component 3 during epithelial-to-mesenchymal transition in human prostate cancer. Oncotarget. 2017;8:39209–39217.
   PubMed Web of Science ®Google Scholar
• Nurdin A, Hoshi Y, Yoneyama T, et al. Global and targeted proteomics of prostate cancer cell secretome: combination of 2-dimensional image-converted analysis of liquid chromatography and mass spectrometry and in silico selection selected reaction monitoring analysis. J Pharm Sci. 2016;105:3440–3452.
   PubMed Web of Science ®Google Scholar
• Narain NR, Diers AR, Lee A, et al. Identification of filamin-A and -B as potential biomarkers for prostate cancer. Future Sci OA. 2017;3:FSO161.
   PubMed Web of Science ®Google Scholar
• Sung E, Kwon OK, Lee J-M, et al. Proteomics approach to identify novel metastatic bone markers from the secretome of PC-3 prostate cancer cells. Electrophoresis. 2017;38(20):2638-2645.
   Web of Science ®Google Scholar
• Waltering KK, Urbanucci A, Visakorpi T. Androgen receptor (AR) aberrations in castration-resistant prostate cancer. Mol Cell Endocrinol. 2012;360:38–43.
   PubMed Web of Science ®Google Scholar
• Saraon P, Cretu D, Musrap N, et al. Quantitative proteomics reveals that enzymes of the ketogenic pathway are associated with prostate cancer progression. Mol Cell Proteomics MCP. 2013;12:1589–1601.
   PubMed Web of Science ®Google Scholar
• Höti N, Shah P, Hu Y, et al. Proteomics analyses of prostate cancer cells reveal cellular pathways associated with androgen resistance. Proteomics. 2017;17(6).
   Web of Science ®Google Scholar
• Shah P, Wang X, Yang W, et al. Integrated proteomic and glycoproteomic analyses of prostate cancer cells reveal glycoprotein alteration in protein abundance and glycosylation. Mol Cell Proteomics MCP. 2015;14:2753–2763.
   PubMed Web of Science ®Google Scholar
• Lescarbeau RM, Kaplan DL. Quantitative analysis of castration resistant prostate cancer progression through phosphoproteome signaling. BMC Cancer. 2014;14:325.
   PubMed Web of Science ®Google Scholar
• Ino Y, Arakawa N, Ishiguro H, et al. Phosphoproteome analysis demonstrates the potential role of THRAP3 phosphorylation in androgen-independent prostate cancer cell growth. Proteomics. 2016;16:1069–1078.
   PubMed Web of Science ®Google Scholar
• Karagiannis GS, Saraon P, Jarvi KA, et al. Proteomic signatures of angiogenesis in androgen-independent prostate cancer. The Prostate. 2014;74:260–272.
   PubMed Web of Science ®Google Scholar
• Lee BY, Hochgräfe F, Lin H-M, et al. Phosphoproteomic profiling identifies focal adhesion kinase as a mediator of docetaxel resistance in castrate-resistant prostate cancer. Mol Cancer Ther. 2014;13:190–201.
   PubMed Web of Science ®Google Scholar
• Chang L, Ni J, Beretov J, et al. Identification of protein biomarkers and signaling pathways associated with prostate cancer radioresistance using label-free LC-MS/MS proteomic approach. Sci Rep. 2017;7:41834.
   PubMed Web of Science ®Google Scholar
• Wells TS, Bukowinski AT, Smith TC, et al. Racial differences in prostate cancer risk remain among US servicemen with equal access to care. The Prostate. 2010;70:727–734.
   PubMed Web of Science ®Google Scholar
• Chornokur G, Dalton K, Borysova ME, et al. Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer. The Prostate. 2011;71:985–997.
   PubMed Web of Science ®Google Scholar
• Myers JS, Vallega KA, White J, et al. Proteomic characterization of paired non-malignant and malignant African-American prostate epithelial cell lines distinguishes them by structural proteins. BMC Cancer. 2017;17:480.
   PubMed Web of Science ®Google Scholar
• Larkin SET, Johnston HE, Jackson TR, et al. Detection of candidate biomarkers of prostate cancer progression in serum: a depletion-free 3D LC/MS quantitative proteomics pilot study. Br J Cancer. 2016;115:1078–1086.
   PubMed Web of Science ®Google Scholar
• Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics MCP. 2002;1:845–867.
   PubMed Web of Science ®Google Scholar
• Tsaur I, Thurn K, Juengel E, et al. sE-cadherin serves as a diagnostic and predictive parameter in prostate cancer patients. J Exp Clin Cancer Res CR. 2015;34:43.
   PubMed Web of Science ®Google Scholar
• Nordström M, Wingren C, Rose C, et al. Identification of plasma protein profiles associated with risk groups of prostate cancer patients. Proteomics Clin Appl. 2014;8:951–962.
   PubMed Web of Science ®Google Scholar
• Sugie S, Mukai S, Yamasaki K, et al. Significant association of Caveolin-1 and caveolin-2 with prostate cancer progression. Cancer Genomics Proteomics. 2015;12:391–396.
   PubMed Web of Science ®Google Scholar
• Wu D, Ni J, Beretov J, et al. Urinary biomarkers in prostate cancer detection and monitoring progression. Crit Rev Oncol Hematol. 2017;118:15–26.
   PubMed Web of Science ®Google Scholar
• Davalieva K, Kiprijanovska S, Komina S, et al. Proteomics analysis of urine reveals acute phase response proteins as candidate diagnostic biomarkers for prostate cancer. Proteome Sci. 2015;13:2.
   PubMed Web of Science ®Google Scholar
• Jedinak A, Curatolo A, Zurakowski D, et al. Novel non-invasive biomarkers that distinguish between benign prostate hyperplasia and prostate cancer. BMC Cancer. 2015;15:259.
   PubMed Web of Science ®Google Scholar
• Jayapalan JJ, Ng KL, Shuib AS, et al. Urine of patients with early prostate cancer contains lower levels of light chain fragments of inter-alpha-trypsin inhibitor and saposin B but increased expression of an inter-alpha-trypsin inhibitor heavy chain 4 fragment. Electrophoresis. 2013;34:1663–1669.
   PubMed Web of Science ®Google Scholar
• Li C, Zang T, Wrobel K, et al. Quantitative urinary proteomics using stable isotope labelling by peptide dimethylation in patients with prostate cancer. Anal Bioanal Chem. 2015;407:3393–3404.
   PubMed Web of Science ®Google Scholar
• Jia X, Chen J, Sun S, et al. Detection of aggressive prostate cancer associated glycoproteins in urine using glycoproteomics and mass spectrometry. Proteomics. 2016;16:2989–2996.
   PubMed Web of Science ®Google Scholar
• Adeola HA, Soares NC, Paccez JD, et al. Discovery of novel candidate urinary protein biomarkers for prostate cancer in a multiethnic cohort of South African patients via label-free mass spectrometry. Proteomics Clin Appl. 2015;9:597–609.
   PubMed Web of Science ®Google Scholar
• Kim Y, Ignatchenko V, Yao CQ, et al. Identification of differentially expressed proteins in direct expressed prostatic secretions of men with organ-confined versus extracapsular prostate cancer. Mol Cell Proteomics MCP. 2012;11:1870–1884.
   PubMed Web of Science ®Google Scholar
• Kim Y, Jeon J, Mejia S, et al. Targeted proteomics identifies liquid-biopsy signatures for extracapsular prostate cancer. Nat Commun. 2016;7:11906.
   PubMed Web of Science ®Google Scholar
• Pilch B, Mann M. Large-scale and high-confidence proteomic analysis of human seminal plasma. Genome Biol. 2006;7:R40.
   PubMed Web of Science ®Google Scholar
• Neuhaus J, Schiffer E, von Wilcke P, et al. Seminal plasma as a source of prostate cancer peptide biomarker candidates for detection of indolent and advanced disease. PloS One. 2013;8:e67514.
   PubMed Web of Science ®Google Scholar
• Neuhaus J, Schiffer E, Mannello F, et al. Protease expression levels in prostate cancer tissue can explain prostate cancer-associated seminal biomarkers - an explorative concept study. Int J Mol Sci. 2017;18(5):976.
   Web of Science ®Google Scholar
• Duijvesz D, Burnum-Johnson KE, Gritsenko MA, et al. Proteomic profiling of exosomes leads to the identification of novel biomarkers for prostate cancer. PloS One. 2013;8:e82589.
   PubMed Web of Science ®Google Scholar
• Bijnsdorp IV, Rozendaal L, van Moorselaar RJA, et al. A predictive role for noncancerous prostate cells: low connexin-26 expression in radical prostatectomy tissues predicts metastasis. Br J Cancer. 2012;107:1963–1968.
   PubMed Web of Science ®Google Scholar
• Bijnsdorp IV, Geldof AA, Lavaei M, et al. Exosomal ITGA3 interferes with non-cancerous prostate cell functions and is increased in urine exosomes of metastatic prostate cancer patients. J Extracell Vesicles. 2013;2:22097.
   Google Scholar
• Øverbye A, Skotland T, Koehler CJ, et al. Identification of prostate cancer biomarkers in urinary exosomes. Oncotarget. 2015;6:30357–30376.
   PubMed Web of Science ®Google Scholar
• Sequeiros T, Rigau M, Chiva C, et al. Targeted proteomics in urinary extracellular vesicles identifies biomarkers for diagnosis and prognosis of prostate cancer. Oncotarget. 2017;8:4960–4976.
   PubMed Web of Science ®Google Scholar
• Welton JL, Brennan P, Gurney M, et al. Proteomics analysis of vesicles isolated from plasma and urine of prostate cancer patients using a multiplex, aptamer-based protein array. J Extracell Vesicles. 2016;5:31209.
   PubMed Web of Science ®Google Scholar
• Fujita K, Kume H, Matsuzaki K, et al. Proteomic analysis of urinary extracellular vesicles from high Gleason score prostate cancer. Sci Rep. 2017;7:42961.
   PubMed Web of Science ®Google Scholar
• Kawakami K, Fujita Y, Kato T, et al. Integrin β4 and vinculin contained in exosomes are potential markers for progression of prostate cancer associated with taxane-resistance. Int J Oncol. 2015;47:384–390.
   PubMed Web of Science ®Google Scholar
• Kharaziha P, Chioureas D, Rutishauser D, et al. Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel. Oncotarget. 2015;6:21740–21754.
   PubMed Web of Science ®Google Scholar
• Ankerst DP, Thompson IM. Sensitivity and specificity of prostate-specific antigen for prostate cancer detection with high rates of biopsy verification. Arch Ital Urol Androl Organo Uff Soc Ital Ecogr Urol E Nefrol. 2006;78:125–129.
   PubMedGoogle Scholar
• Shoag J, Barbieri CE. Clinical variability and molecular heterogeneity in prostate cancer. Asian J Androl. 2016;18:543–548.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.
   PubMed Web of Science ®Google Scholar
• Hamdy FC, Donovan JL, Lane JA, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016;375:1415–1424.
   PubMed Web of Science ®Google Scholar